Bellicum Pharmaceuticals, Inc.

Clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies

The Company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T, TCR and allogeneic T cell therapies. Its lead product candidate, rivo-cel, is an allogeneic polyclonal T cell product that has shown promising results in reducing leukemia relapse after a stem cell transplant. Bellicum’s lead GoCAR-T candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms.

December 1, 2018 in Bellicum Pharmaceuticals, Inc., Portfolio

Bellicum Pharmaceuticals, Inc.: Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018

Interim results suggest rivo-cel outcomes were comparable to a control study of transplants from matched unrelated donors, a requirement for product registration in Europe Company on track to report final results…
Read More
December 1, 2018 in Bellicum Pharmaceuticals, Inc., Portfolio

Bellicum Pharmaceuticals, Inc.: Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant

Experience to date in clinical study shows high clinical response rates for patients with visceral GvHD or GvHD that was refractory to standard of care treatment SAN DIEGO, Dec. 01, 2018 (GLOBE…
Read More
November 1, 2018 in Bellicum Pharmaceuticals, Inc., Portfolio

Bellicum Pharmaceuticals, Inc.: Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting

Nine abstracts accepted, including two oral presentations HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited…
Read More